Aciclovir 200mg/5ml oral suspension sugar free

Țară: Regatul Unit

Limbă: engleză

Sursă: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredient activ:

Aciclovir

Disponibil de la:

Thame Laboratories Ltd

Codul ATC:

J05AB01

INN (nume internaţional):

Aciclovir

Dozare:

40mg/1ml

Forma farmaceutică:

Oral suspension

Calea de administrare:

Oral

Clasă:

No Controlled Drug Status

Tip de prescriptie medicala:

Valid as a prescribable product

Rezumat produs:

BNF: 05030201; GTIN: 5055935100580

Caracteristicilor produsului

OBJECT 1
ACICLOVIR 200MG/5ML ORAL SUSPENSION
Summary of Product Characteristics Updated 23-May-2018 | Thame
Laboratories
1. Name of the medicinal product
Aciclovir 200mg/5ml Oral Suspension
2. Qualitative and quantitative composition
The active substance is aciclovir.
Each 5ml of oral suspension contains 200mg aciclovir.
_Excipient(s) with known effect:_
Each 5ml of suspension contains 2.25g sorbitol liquid
(non-crystallising) (E420) and 10mg of methyl
parahydroxybenzoate (E218).
For the full list of excipients, see section 6.1
3. Pharmaceutical form
Oral Suspension
White to off-white uniform oral suspension with orange and vanilla
odour
4. Clinical particulars
4.1 Therapeutic indications
Aciclovir Suspension is indicated for the treatment of herpes simplex
virus infections of the skin and
mucous membranes including initial and recurrent genital herpes
(excluding neonatal HSV and severe
HSV infections in immunocompromised children).
Aciclovir Suspension is indicated for the suppression (prevention of
recurrences) of recurrent herpes
simplex infections in immunocompetent patients.
Aciclovir Suspension is indicated for the prophylaxis of herpes
simplex infections in
immunocompromised patients.
Aciclovir Suspension is indicated for the treatment of varicella
(chickenpox) and herpes zoster (shingles)
infections.
4.2 Posology and method of administration
_Dosage in Adults _
_Treatment of herpes simplex infections_
_ _
_ _:
_ _
200mg Aciclovir suspension should be taken five times daily at
approximately four hourly intervals
omitting the night time dose. Treatment should continue for 5 days,
but in severe initial infections this
may have to be extended.
In severely immunocompromised patients (e.g. after marrow transplant)
or in patients with impaired
absorption from the gut the dose can be doubled to 400mg Aciclovir
suspension or alternatively
intravenous dosing could be considered.
Dosing should begin as early as possible after the start of an
infection; for recurrent episodes this should
preferably be during the prod